

## Synthesis and Antimicrobial Activity of Optically Active *trans*-Cycloheximide Isomers

Sachio KUDO, Takayuki ORITANI and Kyohei YAMASHITA

Department of Agricultural Chemistry, Faculty of Agriculture,  
Tohoku University, Sendai 980, Japan

Received March 13, 1984

Optically active *trans*-cycloheximide isomers such as cycloheximide [(2*S*,4*S*,6*R*, $\alpha$ *R*)-form (1)], naramycin B[(2*S*,4*S*,6*R*, $\alpha$ *R*)-form (4)], and new stereoisomers (2*S*,4*S*,6*S*, $\alpha$ *S*)-form (8) and (2*S*,4*S*,6*R*, $\alpha$ *S*)-form (9) were synthesized by an aldol condensation of *trans*-2,4-dimethyl-1-cyclohexanone (5b), with 4-(2-oxoethyl)-2,6-piperidinedione (6). The antimicrobial activity of *trans*-cycloheximide isomers (1, 4, 8, and 9) was examined against *S. cerevisiae* and *P. oryzae*. The stereoisomers 1 and 4 exhibited marked antimicrobial activity against both microorganisms as compared with their C- $\alpha$ -epimers 8 and 9.

Cycloheximide (1) is a powerful antimicrobial agent isolated from the cultured broth of *Streptomyces griseus*.<sup>1)</sup> The stereochemistry of 1 has been elucidated by Johnson *et al.*<sup>2)</sup> and confirmed by X-ray analysis.<sup>3)</sup> Among the stereoisomers of 1, isocycloheximide [(2*R*,4*S*,6*R*, $\alpha$ *R*)-form (2)],  $\alpha$ -epi-isocycloheximide [(2*R*,4*S*,6*R*, $\alpha$ *S*)-form (3)] and naramycin B (4) are known in nature. Antimicrobial activity of cycloheximide isomers is unknown except for natural ones. Based on the stereochemical relationship of the 2,4-dimethyl-1-cyclohexanone (2,4-DMC) moiety, the stereoisomers of 1 are classified into two groups: *cis*-cycloheximide isomers containing *cis*-2,4-DMC and *trans*-cycloheximide isomers containing *trans*-2,4-DMC. Synthesis of *cis*-cycloheximide isomers (2 and 3)<sup>4,5)</sup> was easily accomplished by an aldol condensation (Nielsen condensation) of the magnesium enolate 7a prepared from *cis*-2,4-DMC (5a) with the aldehyde 6. The synthesis of *trans*-cycloheximide isomers (1 and 4) was more difficult. Johnson *et al.*<sup>6)</sup> have synthesized 1 through condensation of the enamine, prepared from *cis*-2,4-DMC (5a), with the aldehyde 6 in a low yield. Okuda *et al.*<sup>4)</sup> have obtained  $\alpha$ -epi-isocycloheximide (3) mainly by a Nielsen condensation of (+)-*trans*-2,4-

DMC (5b) with 6, but did not obtain *trans*-cycloheximide isomers. This result was explained by the epimerization of C-2 position during preparation of the enolate 7a with *N*-methylanilino magnesium bromide. Nevertheless, aldol condensation still seems to be most promising method for the synthesis of *trans*-cycloheximide isomers, because it is the shortest route to synthesize isomers of 1, and many modifications of the reaction with high stereoselectivity are known at the present time. House *et al.*<sup>7)</sup> have reported a lithium-mediated *threo* selective aldol condensation of cyclic ketones, and Kuwajima *et al.* have reported a titanium-<sup>8)</sup> and tin-<sup>9)</sup> mediated *erythro* selective aldol reaction of cyclic ketones. Therefore, we reinvestigated the synthesis of *trans*-cycloheximide isomers by a revised aldol condensation using these useful metal reagents.

Firstly, aldol condensation of the lithium enolate 7b, prepared from the (+)-*trans*-ketone 5b,<sup>10)</sup> with the aldehyde 6 was investigated. The lithium enolate 7b, generated from the ketone 5b and lithium diisopropylamide (LDA), was reacted with the aldehyde 6<sup>5)</sup> at  $-70^{\circ}\text{C}$  to give a stereoisomeric mixture of *trans*-cycloheximides (1, 4, 8 and 9) (58.0% yield). The mixture was separated into each

component by medium pressure liquid chromatography (MPLC) on silica-gel, and their structures were elucidated by  $^{13}\text{C}$ - and  $^1\text{H}$ -NMR spectra (Tables I and II). The spectral data of synthetic **1** were identical with those of natural cycloheximide (**1**).<sup>12,14</sup> The  $^1\text{H}$ -NMR spectrum of **4** was also in good accordance with that of naramycin B (**4**).<sup>11</sup> Chemical shift differences among the methyl carbons afforded




FIG. 1. Structure of Natural Cycloheximide Isomers.




FIG. 2.

an important indication for assignment of the stereochemistry of the 2,4-DMC moiety on cycloheximides. As the chemical shifts of the methyl carbons ( $\delta$  14.0, 18.4 ppm) of **8** coincided well with those of **1** ( $\delta$  14.2, 18.4 ppm), it is clear that **8** has *equatorial* C-2 methyl and *axial* C-4-methyl groups. It is also apparent that **9** has *axial* C-2-methyl and *equatorial* C-4-methyl groups from the agreement of the methyl signals between **9** ( $\delta$  17.7, 21.6 ppm) and **4** ( $\delta$  17.6, 21.5 ppm). The splitting pattern of the C- $\alpha$ -proton was a good indicator to assign the C- $\alpha$ -stereochemistry of the stereoisomers (**1**, **4**, **8** and **9**) as shown in Table II. After exchanging a hydroxyl proton with  $\text{D}_2\text{O}$ , signals of a C- $\alpha$ -proton in **1** (*erythro* aldol) and **9** showed d-d-d coupling (**1**:  $J=10.2, 5.4, 5.4\text{ Hz}$ ; **9**:  $J=10.5, 5.3, 5.3\text{ Hz}$ ). This fact showed that **9** is *erythro* aldol. As the splitting

TABLE I.  $^{13}\text{C}$ -NMR DATA FOR SYNTHETIC CYCLOHEXIMIDES

Compound	Chemical shifts <sup>a</sup> of methyl signals (ppm)	
	At C-2	At C-4
<b>1</b>	14.2	18.4
<b>1</b> <sup>b</sup>	14.2 ( <i>eq</i> )	18.4 ( <i>ax</i> )
<b>4</b>	17.6 ( <i>ax</i> )	21.5 ( <i>eq</i> )
<b>8</b>	14.0	18.4
<b>9</b>	17.7	21.6

<sup>a</sup> The known orientation of methyl groups is shown in brackets: *eq*, equatorial; *ax*, axial.

<sup>b</sup> Reported data, see ref. 12.

TABLE II.  $^1\text{H}$ -NMR DATA FOR SYNTHETIC CYCLOHEXIMIDE ISOMERS

Compound	Chemical shifts, ppm (JHz)	
	Methyl proton	C- $\alpha$ -Proton
<b>1</b>	0.99 (6.4), 1.25 (7.1)	4.2 (d-d-d, $J=10.2, 5.4, 5.4$ )
<b>1</b> <sup>a</sup>	0.98 (6.1), 1.23 (6.7)	4.1 <sup>b</sup>
<b>4</b>	0.99 (6.3), 1.22 (7.3)	3.8 (m)
<b>4</b> <sup>a</sup>	0.98 (5.9), 1.21 (7.4)	3.7 <sup>b</sup>
<b>8</b>	0.99 (6.4), 1.26 (6.8)	3.8 (m)
<b>9</b>	1.00 (6.3), 1.22 (7.6)	4.2 (d-d-d, $J=10.5, 5.3, 5.3$ )

<sup>a</sup> Data of natural products. See ref. 11.  $^1\text{H}$ -NMR spectra of the authentic **1** (mp 115~116°C), obtained by recrystallization of commercially available reagent (purchased from Nakarai Chemical Co., Ltd.) agreed completely with that of synthetic **1**.

<sup>b</sup> Coupling constants are not described.

pattern of the C- $\alpha$  proton in **4** (*threo* aldol) and **8** is multiplet, **8** was deduced to be *threo* aldol.

Next, an aldol reaction of the trichlorotitanium enolate **7c** and trichlorotin enolate **7d** with the aldehyde **6** were individually examined. The enolates, **7c** and **7d** were prepared by reaction of the silyl enol ether **7e** with titanium tetrachloride and tin tetrachloride, respectively. Both enolates **7c** and **7d** were reacted with the aldehyde **6** at  $-45^{\circ}\text{C}$  to give a mixture of *trans*-cycloheximide isomers in a low yield (19.2% and 8.2%). As shown in Table III, the reaction products from the enolate **7c** contained a higher content of *erythro* aldol (**1** and **9**) than those from the lithium enolate **7b**. In the case of enolate **7d**, the isomer **4** was produced as a main product.

These results show that an aldol condensation of the *trans*-ketone **5b** with the aldehyde **6** afforded *trans*-cycloheximide isomers as expected, although the reaction yield and content of cycloheximide (**1**) were low.

Finally, the antimicrobial activity of *trans*-cycloheximide isomers (**1**, **4**, **8** and **9**) was examined against *Saccharomyces cerevisiae* and *Pyricularia oryzae* (Table IV). The stereoisomers **1** and **4** showed marked antimicrobial activity against both microorganisms

as compared with their C- $\alpha$ -epimers **8** and **9**. Especially, **8**, a C- $\alpha$ -epimer of cycloheximide, did not show growth inhibition against *S. cerevisiae*. Recently, Berg *et al.*<sup>15)</sup> have reported that natural naramycin B (**4**) inhibited the growth of yeasts and some phyto-




FIG. 3.

TABLE III. COMPOSITION OF *trans*-CYCLOHEXIMIDE ISOMERS

Enolate	Compound No.			
	1	4	8	9
<b>7b</b>	2.8 <sup>a</sup>	37.5	50.3	9.4
<b>7c</b>	28.9	21.1	31.6	18.4
<b>7d</b>	9.5	69.7	—	20.8

<sup>a</sup> % composition of each isomer in *trans*-cycloheximide isomers obtained by aldol condensation.

TABLE IV. ANTIMICROBIAL ACTIVITY OF *trans*-CYCLOHEXIMIDE ISOMERS

Compounds	Concentration ( $\mu\text{g}/\text{disc}$ )	Inhibited zone (mm)			
		<i>S. cerevisiae</i> (HUT 7099)		<i>P. oryzae</i> (IFO 5279)	
		48 hr	72 hr	48 hr	72 hr
2 <i>S</i> ,4 <i>S</i> ,6 <i>S</i> , $\alpha$ <i>R</i> -form ( <b>1</b> )	1	27.0	25.0	19.0	17.0
	10	36.0	35.0	51.0	43.0
	100	43.0	40.0	59.0	58.0
2 <i>S</i> ,4 <i>S</i> ,6 <i>R</i> , $\alpha$ <i>R</i> -form ( <b>4</b> )	1	—	—	13.0	—
	10	20.0	20.0	17.0	13.0
	100	34.0	32.0	33.0	31.5
2 <i>S</i> ,4 <i>S</i> ,6 <i>S</i> , $\alpha$ <i>S</i> -form ( <b>8</b> )	100	—	—	14.5	14.0
2 <i>S</i> ,4 <i>S</i> ,6 <i>R</i> , $\alpha$ <i>S</i> -form ( <b>9</b> )	10	10.0	10.0	14.5	11.0
	100	17.0	17.0	19.0	17.5

pathogens. Our results reconfirmed the strong antimicrobial activity of **4**.

Further work is under way to synthesize the optically active *cis*-cycloheximide isomers from (+)- and (–)-*cis*-2,4-DMC (**5a**).<sup>13)</sup>

## EXPERIMENTAL

All boiling points and melting points are uncorrected. <sup>1</sup>H-NMR and <sup>13</sup>C-NMR spectra were recorded on a JEOL JNM FX-100 spectrometer. IR spectra were recorded on a JASCO IR-810 infrared spectrometer. Optical rotations were measured on a JASCO DIP-4 spectrometer. Circular dichroism (CD) spectra were measured on a Dichrograph Mark III-J spectrometer using a 1 cm cell in MeOH. Gas chromatographic analyses were performed on a JEOL JGC-1100 instrument with a thermal conductance detector and stainless steel column (2 m × 3 mm) packed with 20% DEGS on Chromosorb W (column temp, 95°C; He flow rate, 15 ml/min). High pressure liquid chromatography (HPLC) was performed on a JASCO TRIOTAR instrument with a UV spectrometer (at 254 nm) and stainless steel column (4.6 mm × 250 mm) packed with silica-gel (SS-05) (solvent system: methylene chloride/isopropyl alcohol=98/2; flow rate: 1 ml/min). MPLC were performed on the same instrument using a glass column packed with a silica-gel (Lichroprep Si 60, 40 ~ 63 μm) and using the same solvent system.

1) (+)-*trans*-2,4-Dimethyl-1-cyclohexanone (**5b**). Cycloheximide (**1**) (15 g) was degraded by heating at 220°C to give 2.61 g (38.9%) of the isomeric mixture of 2,4-DMC: 63 ~ 65°C (20 mmHg);  $[\alpha]_D^{20} + 58.3^\circ$  ( $c=30.6$ , EtOH). It consisted of 89.6% of *trans*-2,4-DMC (**5b**) ( $t_R$ : 12.8 min) and 10.4% of *cis*-2,4-DMC (**5a**) ( $t_R$ : 10.8 min) by GLC analysis. The mixture was used in the following reactions.

2) *Alcohol condensation of the lithium enolate 7b with the aldehyde 6*. To a stirred solution of LDA in 50 ml of dry tetrahydrofuran, prepared from 5.7 mmol of *n*-butyllithium and 5.7 mmol of diisopropylamine, was added 720 mg (5.7 mmol) of the ketone **5b** and then 880 mg (5.7 mmol) of the aldehyde **6**<sup>9)</sup> at –70°C. After stirring at –70°C for 30 min, the mixture was poured into ice-cooled dil. acetic acid and extracted with methylene chloride three times. The combined extracts were washed with aq. NaHCO<sub>3</sub>, brine and dried over anhyd. MgSO<sub>4</sub>. Evaporation of the solvent left 1.32 g of an oil, which was chromatographed on silica-gel with a solvent system of methylene chloride/isopropyl alcohol (98/2) to give the starting ketone (205 mg), optically active *trans*-cycloheximide isomers (**1**, **4**, **8** and **9**) (929 mg) and optically active neocycloheximide (**10**)<sup>11)</sup> (131 mg). The optically active *trans*-cycloheximide isomers consisted of 50.3% of **8** ( $t_R$ : 14.0 min), 37.5% of **4** ( $t_R$ : 15.2 min), 2.8%

of **1** ( $t_R$ : 17.0 min) and 9.4% of **9** ( $t_R$ : 18.0 min) by HPLC analysis. Repeated fractionation by MPLC gave pure hydroxy ketones, **8** (91 mg), **4** (99 mg), **1** (9 mg) and **9** (72 mg). The physical data are as follows. **8**: mp 106 ~ 107°C; IR  $\nu_{\max}^{\text{KBr}}$  cm<sup>–1</sup>: 3350, 3190, 3010, 1705, 1375, 1280, 1270, 1120, 875, 820;  $[\alpha]_D^{20} - 23.5^\circ$  ( $c=2.5$ , MeOH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 14.0 (q), 18.4 (q), 27.0, 37.0, 37.2, 38.5, 38.7, 40.8, 42.6, 51.3, 69.0, 172.5, 172.6, 217.0. *Anal.* Found: C, 63.80; H, 8.23; N, 4.97. Calcd. for C<sub>15</sub>H<sub>23</sub>O<sub>4</sub>N: C, 64.03; H, 8.24; N, 4.98%. **4**: mp 117.5 ~ 118.5°C; IR  $\nu_{\max}^{\text{KBr}}$  cm<sup>–1</sup>: 3350, 3220, 3080, 1710, 1380, 1295, 1275, 1150, 1005, 820;  $[\alpha]_D^{20} + 85.6^\circ$  ( $c=0.7$ , MeOH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 17.6 (q), 21.5 (q), 25.9, 27.0, 37.0, 38.1, 38.3, 38.7, 41.2, 44.8, 51.0, 68.7, 172.5, 172.6, 219.2. *Anal.* Found: C, 63.64; H, 8.31; N, 4.97. Calcd. for C<sub>15</sub>H<sub>23</sub>O<sub>4</sub>N: C, 64.03; H, 8.24; N, 4.98%. **1**: mp 110 ~ 111°C; IR  $\nu_{\max}^{\text{KBr}}$  cm<sup>–1</sup>: 3520, 3470, 3200, 3090, 1720, 1685, 1380, 1280, 1270, 1250, 1150; CD ( $c=2 \times 10^{-4}$ , MeOH)  $[\theta]_{\max}$ :  $-0.9 \times 10^3$  ( $\lambda_{\max}$ : 295 nm) (authentic sample<sup>14)</sup>:  $[\theta]_{\max}$ :  $-1.0 \times 10^3$  ( $\lambda_{\max}$ : 295 nm) at the same concentration; <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 14.2 (q), 18.4 (q), 26.7, 27.6, 33.1, 37.3, 37.9, 38.5, 40.5, 42.6, 50.1, 66.6, 172.1, 172.2, 216.3. *Anal.* Found: C, 63.69; H, 8.28; N, 4.96. Calcd. for C<sub>15</sub>H<sub>23</sub>O<sub>4</sub>N: C, 64.03; H, 8.24; N, 4.98%. **9**: mp 98.5 ~ 99.5°C; IR  $\nu_{\max}^{\text{KBr}}$  cm<sup>–1</sup>: 3450, 3260, 1705, 1390, 1270, 1255, 1155, 1110, 830, 810;  $[\alpha]_D^{20} + 74.7^\circ$  ( $c=0.55$ , MeOH); <sup>13</sup>C-NMR (CDCl<sub>3</sub>)  $\delta$ : 17.7 (q), 21.6 (q), 25.9, 27.6, 34.4, 37.2, 37.9, 38.5, 41.1, 44.5, 50.1, 66.6, 172.3, 172.5, 218.2. *Anal.* Found: C, 63.67; H, 8.28; N, 5.03. Calcd. for C<sub>15</sub>H<sub>23</sub>O<sub>4</sub>N: C, 64.03; H, 8.24; N, 4.98%.

3) *Preparation of trimethylsilyl enol ether (TMS ether) 7e*. To a stirred solution of LDA in 50 ml of dry tetrahydrofuran, prepared from 13.4 mmol of *n*-butyllithium and 13.4 mmol of diisopropylamine, was added 1.41 g (11.2 mmol) of the ketone **5b** at –70°C. A few minutes later, 2.0 g of trimethylsilyl chloride was added in one portion. The temperature was maintained for 1 hr and then raised to room temperature. After stirring for 2 hr, the reaction mixture was poured into aq. NaHCO<sub>3</sub> and extracted with *n*-hexane. The extract was washed with brine and dried over anhyd. MgSO<sub>4</sub>. Evaporation of the solvent, followed by distillation under reduced pressure gave an oily **7e** (1.2 g) ( $t_R$ : 3.4 min by GLC analysis): bp 85 ~ 86°C (15 mmHg); IR  $\nu_{\max}^{\text{film}}$  cm<sup>–1</sup>: 2960, 2910, 1670; <sup>1</sup>H-NMR (CDCl<sub>3</sub>)  $\delta$ : 0.93 (3H, d,  $J=5.9$  Hz), 1.05 (3H, d,  $J=6.8$  Hz), 3.7 (1H).

4) *Alcohol condensation of the trichlorotitanium enolate 7c with the aldehyde 6*. To solution of titanium tetrachloride (1 M, 1.5 ml) in methylene chloride, 350 mg (1.7 mmol) of the TMS ether **7e** was added in one portion and stirred for 5 min at 20°C. After cooling to –45°C, 270 mg (1.7 mmol) of the aldehyde **6** in 2 ml of methylene chloride was added at once. The mixture was stirred for 5 min and then poured into aq. NaHCO<sub>3</sub>. After acidification with dil. acetic acid, the mixture was extracted with

methylene chloride. The extract was washed with aq.  $\text{NaHCO}_3$ , brine and dried over anhyd.  $\text{MgSO}_4$ . Evaporation of the solvent gave an oil (255 mg), from which the fraction of *trans*-cycloheximide isomers (95 mg) was collected by MPLC. This consisted of 31.6% of **8** ( $t_R$ : 14.0 min), 21.1% of **4** ( $t_R$ : 15.2 min), 28.9% of **1** ( $t_R$ : 17.0 min) and 18.4% of **9** ( $t_R$ : 18.0 min) by HPLC analysis.

5) *Aldol condensation of the trichlorotin enolate 7d with the aldehyde 6*. To a solution of tin tetrachloride (1 M, 2.0 ml) in methylene chloride, 350 mg of the TMS ether **7e** (1.7 mmol) was added in one portion and the mixture stirred for 10 min at 20°C. After cooling to -45°C, 270 mg (1.7 mmol) of the aldehyde **6** in 2 ml of methylene chloride was added at once. The mixture was stirred for 5 min and then poured into aq.  $\text{NaHCO}_3$ . After acidification with dil. acetic acid, the mixture was extracted with methylene chloride. The extract was washed with aq.  $\text{NaHCO}_3$ , brine and dried over anhyd.  $\text{MgSO}_4$ . Evaporation of the solvent gave an oil (161 mg), from which the fraction of *trans*-cycloheximide isomers (41 mg) was collected by MPLC. This fraction consisted of 69.7% of **4** ( $t_R$ : 15.2 min), 9.5% of **1** ( $t_R$ : 17.0 min) and 20.8% of **9** ( $t_R$ : 18.0 min) by HPLC analysis.

6) *Antimicrobial assay of trans-cycloheximide isomers against Saccharomyces cerevisiae (HUT 7099) and Pyricularia oryzae (IFO 5279)*. The antimicrobial activities of (-)-**1**, (+)-**4**, (-)-**8** and (+)-**9** were determined by the conventional paper disc method against *S. cerevisiae* and *P. oryzae*. Test strains were cultured in a medium containing 2% malt extract, 0.1% peptone, 2% glucose and 0.1% agar at 28°C for 48 hr, and diluted 120 fold with 1% agar medium. The cultured broth of each strain was layered on a Petri dish (diameter 80 mm) and paper discs (8 mm, thin) containing 1, 10 and 100  $\mu\text{g}$  of the respective test samples were placed in position. After 48 and 72 hr at 25°C, the growth inhibitory zones around the discs were measured

to give the results shown in Table IV.

*Acknowledgment.* This work was supported by a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture of Japan.

## REFERENCES

- 1) B. E. Leach, J. H. Ford and A. J. Whiffen, *J. Am. Chem. Soc.*, **69**, 474 (1947).
- 2) F. Johnson, N. A. Starkovsky and A. A. Carlson, *J. Am. Chem. Soc.*, **87**, 4612 (1965).
- 3) J. Sayers, D. Schindler and M. Sundaralingam, *J. Am. Chem. Soc.*, **99**, 3848 (1977).
- 4) M. Suzuki, Y. Egawa and T. Okuda, *Chem. Pharm. Bull.*, **11**, 582 (1963).
- 5) Y. Egawa, M. Suzuki and T. Okuda, *Chem. Pharm. Bull.*, **11**, 589 (1963).
- 6) F. Johnson, N. A. Starkovsky, A. C. Paton and A. A. Carlson, *J. Am. Chem. Soc.*, **88**, 149 (1966).
- 7) H. O. House, D. S. Crumrine, A. Y. Teranishi and H. D. Olmstead, *J. Am. Chem. Soc.*, **95**, 3310 (1973).
- 8) E. Nakamura and I. Kuwajima, *Tetrahedron Lett.*, **24**, 3343 (1983).
- 9) E. Nakamura and I. Kuwajima, *Tetrahedron Lett.*, **24**, 3347 (1983).
- 10) B. C. Lawes, *J. Am. Chem. Soc.*, **84**, 239 (1962).
- 11) F. Johnson, N. A. Starkovsky and W. D. Gurowitz, *J. Am. Chem. Soc.*, **87**, 3492 (1965).
- 12) P. W. Jeffs and D. McWilliams, *J. Am. Chem. Soc.*, **103**, 6185 (1981).
- 13) T. Oritani, S. Kudo and K. Yamashita, *Agric. Biol. Chem.*, **46**, 757 (1982).
- 14) See footnote a), Table II.
- 15) D. Berg, M. Schedel, R. R. Schmidt, K. Ditgens and H. Weyland, *Z. Naturforsch., Teil C: Biosci.*, **37C**, 1100 (1982).